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B cell precursor ALL is the most common pediatric malignancy. 
Children with affected siblings have 2- to 4-fold greater risk of devel-
oping the disease4, and, in occasional cases, ALL is inherited as a 
mendelian disorder5. PAX5, encoding the B cell lineage transcrip-
tion factor paired box 5, is somatically deleted, rearranged or other-
wise mutated in approximately 30% of sporadic B-ALL cases1–3,6–9. 
In Pax5-deficient mice, B cell development is arrested at the pro- 
B cell stage, and these cells can differentiate in vitro into other lym-
phoid and myeloid lineages10. PAX5 is also essential for maintaining 
the identity and function of mature B cells11, and its deletion in 
mature B cells results in dedifferentiation to pro-B cells and aggres-
sive lymphomagenesis12.
We identified a heterozygous germline PAX5 variant, c.547G>A 
(NM_016734), encoding p.Gly183Ser (NP_057953), by exome 
sequencing in two families, one of Puerto Rican ancestry (family 1; 
Fig. 1a) and the other of African-American ancestry (family 2; Fig. 1b 
and Supplementary Note). This variant had not previously been 
described in public databases (Exome Variant Server, 1000 Genomes 
Project and dbSNP137) or previous sequencing analyses of ALL and 
cancer genomes1,2,9. All affected family members had B-ALL, and all 
available diagnostic and relapse leukemic samples from both families 
demonstrated loss of 9p through the formation of an isochromosome 
of 9q, i(9)(q10), or the presence of dicentric chromosomes involv-
ing 9q, both of which resulted in loss of the wild-type PAX5 allele 
and retention of the PAX5 allele encoding p.Gly183Ser (Fig. 1c, 
Supplementary Fig. 1 and Supplementary Table 1).
The germline PAX5 mutation encoding p.Gly183Ser segregated 
with leukemia in both kindreds; however, several unaffected obligate 
carriers (family 1: II3, III2 and III3 and family 2: I1, I2, II2 and II3) 
were also observed, suggesting incomplete penetrance. Unaffected 
mutation carriers and affected individuals at the time of diagnosis 
with ALL had normal immunoglobulin levels and no laboratory or 
clinical evidence of impaired B cell function. Sanger sequencing of 
cDNA from the peripheral blood of unaffected carriers indicated 
biallelic transcription of PAX5 (data not shown). The only mutated 
gene common to both families was PAX5, and no germline copy 
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number aberrations were found to be shared 
by affected individuals (Supplementary 
Tables 2 and 3).
To determine whether the mutation encod-
ing p.Gly183Ser arose independently in each 
kindred or instead reflects common ancestry, we compared the risk 
haplotypes of the families. The families shared a 4.7-kb haplotype 
spanning five SNPs (Fig. 1d and Supplementary Note). The relatively 
small size of this shared haplotype and principal-component analysis 
of genome-wide SNP genotype data (Supplementary Fig. 2) together 
implied that the two families were not recently related and differed in 
ancestry. Moreover, given the reduced fitness due to increased sus-
ceptibility to childhood ALL, it is unlikely that such a lethal mutation 
could be propagated over time. Because the identified haplotype is 
relatively frequent worldwide (Supplementary Table 4), it is likely 
that each family’s mutation arose independently.
Genomic profiling of tumor samples demonstrated expression of 
the mutant PAX5 allele encoding p.Gly183Ser in diagnostic and relapse 
tumor specimens from affected members of family 2, with an average 
of 1 chimeric fusion and 9 non-silent sequence variants per case and 
homozygous deletion of CDKN2A with or without CDKN2B in all 
cases due to loss of 9p and focal deletion of the second allele. Apart 
from loss of 9p, no other somatic sequence mutations or structural 
rearrangements were shared by the affected families (Supplementary 
Tables 1 and 5–12).
As somatic i(9)(q10) or dic(9;v) abnormalities were seen in all 
of the familial leukemias, we sequenced PAX5 in 44 additional 
sporadic pre-B-ALL cases with i(9)(q10) or dic(9;v) aberrations to 
assess whether PAX5 mutations frequently co-occur with loss of 9p. 
Two leukemic samples had mutations encoding p.Gly183Ser and 
p.Gly183Val substitutions in the octapeptide domain, and, in others, 
previously reported variants including p.Pro80Arg and p.Val26Gly1 
were observed (Fig. 2 and Table 1). We examined the frequency 
of non-silent PAX5 somatic sequence mutations in a cohort of 
B-ALL cases with 9p loss through i(9)(q10) or dic(9;v) aberrations 
(n = 28) and in 2 cohorts of B-ALL without i(9)(q10) or dic(9;v) 
aberrations (n = 183 and 221; refs. 1,2). We observed a significantly 
higher frequency of PAX5 mutations in the cohort with isochro-
mosomal or dicentric aberrations of chromosome 9 (P = 0.0001). 
No germline PAX5 mutations were detected in 39 families with a 
history of 2 or more cases of cancer, including at least 1 childhood 
hematological cancer, although 1 familial case of ALL harbored 
a dic(9;20)(p11;q11.1) alteration and a somatic variant encoding 
p.Pro80Arg (Table 1 and Supplementary Note).
Previously identified PAX5 somatic mutations commonly result in 
marked reduction in the transcriptional activation mediated by PAX5. 
Downstream targets of PAX5 include CD19 and CD79A (also known as 
IGA and MB-1)13. We examined the transactivating activity of the pro-
teins encoded by the wild-type and mutant PAX5 alleles using a PAX5-
dependent reporter gene assay containing copies of a high-affinity 
PAX5-binding site derived from the CD19 promoter14. Both the 
p.Gly183Ser and p.Gly183Val alterations resulted in partial but sig-
nificant reduction in transcriptional activation compared to wild-type 
PAX5 (P < 0.0001 for both alterations; Fig. 3a). Additionally, there was 
no detectable difference in the subcellular localization of wild-type and 
p.Gly183Ser PAX5 (Supplementary Fig. 3). To study the effect of the 
p.Gly183Ser alteration on CD79A expression, we expressed mutant 
and wild-type PAX5 in J558 and J558LµM, mouse plasmacytoma cell 
lines that do not express PAX5 or CD79A. Enforced expression of 
PAX5 results in expression of CD79A and assembly of the surface 
immunoglobulin M (sIgM) complex. The amount of sIgM expression 
may be used to assess the transcriptional activity of  PAX5 alleles on the 
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Figure 1 Familial pre-B cell ALL associated 
with i(9)(q10) and dic(9;v) alterations in two 
families harboring a new, recurrent germline 
variant encoding p.Gly183Ser. (a) Family 1 of 
Puerto Rican ancestry. The proband is indicated 
by an arrow. Exome sequencing was undertaken 
on germline DNA from all available affected 
(IV1, IV5, IV6, III5) and unaffected (IV9, III3, 
III4) individuals as well as on the diagnostic 
leukemic sample from IV6. (b) Family 2 of 
African-American ancestry. The proband is 
indicated by an arrow. Exome sequencing was 
undertaken in diagnostic, remission and relapse 
leukemic samples from individuals III4, IV1 and 
IV2. (c) Chromosome 9 copy number heatmap 
for SNP6.0 microarray data of germline and 
tumor samples from three members of family 2.  
These data demonstrate the common feature 
of loss of 9p in the tumor specimens. Note the 
focal dark-blue band denoting homozygous loss 
of CDKN2A and/or CDKN2B in all samples. 
Blue indicates deletions, and red indicates 
gains. G, germline; D, diagnostic; R, relapse. 
(d) Haplotype flanking the mutation encoding 
p.Gly183Ser. A five-SNP haplotype from 
rs7850825 to rs7020413 (chr. 9: 36.997–
37.002 Mb) proximal to the mutation was 
concordant in both family 1 and family 2. 
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resulted in a significant reduction in sIgM expression compared to 
the wild-type PAX5 allele (P < 0.0001; Fig. 3b). These results suggest 
that PAX5 mutations affecting Gly183 result in partial loss of PAX5 
activity.
The identified missense variant p.Gly183Ser is located at a con-
served residue in the octapeptide domain of PAX5 that mediates inter-
action with Groucho transcriptional corepressors15 (Fig. 2b). Previous 
studies have shown that GRG4 (also known as TLE4) represses PAX5-
dependent luciferase activity in cells expressing wild-type PAX5 but 
not in cells expressing PAX5 octapeptide-domain mutants15. We 
observed GRG4-mediated repression of the transcriptional activity of 
wild-type and p.Gly183Ser PAX5 (Fig. 3c), suggesting that the effect 
of the alteration is not mediated by altered 
interaction with GRG4.
To further explore the effect of the 
p.Gly183Ser variant on downstream targets, 
we performed genome-wide transcriptional 
profiling of J558LµM cells transduced with 
empty vector or with vector expressing 
wild-type or mutant PAX5 alleles (examin-
ing either all transduced cells marked by red 
fluorescent protein (RFP) expression or the 
subset of cells expressing sIgM) and ana-
lyzed the expression of genes activated and 
repressed by PAX5 as previously defined 
in Pax5−/− mouse pro-B cells and mature 
B cells16–19 and in human ETV6-RUNX1–
positive B-ALL1. Examining all PAX5- 
expressing cells, we observed profound 
deregulation of genes activated and 
repressed by PAX5 in J558LµM cells 
expressing known loss-of-function alleles 
(for example, the common exon 2–6 deletion 
that results in a truncating frameshift PAX5 
allele, ∆2–6) or strongly hypomorphic alle-
les (for example, the PAX5 allele encoding 
p.Pro80Arg) and less marked deregulation in 
cells expressing p.Gly183Ser or p.Gly183Val 
mutant PAX5 (P values for each mutant protein versus wild type were all 
P < 0.001; Supplementary Figs. 4 and 5). Comparing sorted sIgM-
positive cells expressing p.Gly183Ser PAX5 to those expressing wild-
type protein, we observed reduced expression of genes activated by 
PAX5 in pro-B cells and mature B cells (P = 1.4 × 10−4 and 3.8 × 10−4, 
respectively; Supplementary Tables 13–15).
We next examined the transcriptional consequences of the PAX5 
mutation encoding p.Gly183Ser by performing transcriptome 
sequencing (mRNA-seq) of diagnostic and relapse samples obtained 
from 2 affected individuals in kindred 2 and from 139 sporadic child-
hood B-ALL samples. We performed gene-set enrichment analysis 
incorporating gene sets of PAX5-mutated, ETV6-RUNX1–positive 
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Figure 2 Recurrent PAX5 mutations in ALL. (a) Gene schematic of PAX5 (NM_016734) showing the exons, amino acid residues, protein domains 
and position of the germline variant encoding p.Gly183Ser (red) in relation to the somatic PAX5 mutations described in this study (n = 13, arrows) 
and somatic mutations described previously in B-ALL1,2,20. Primary leukemic samples with confirmed retention of the germline variant encoding 
p.Gly183Ser are denoted by squares (family 1) and diamonds (family 2). In one case of ALL with a dicentric aberration of chromosome 9, we found both 
a heterozygous mutation encoding p.Val26Gly and a heterozygous mutation encoding p.Gln350fs, indicating polyclonality of the tumor. (b) Conservation 
of the octapeptide domain in selected PAX family members.
table 1 PAX5 mutations found in familial and sporadic B-All samples with i(9)(q10) or 
dic(9;v) aberrations
Inheritance Subject Mutation Protein alteration Tumor status Germline status
Family 1 IV6 c.547G>A p.Gly183Ser Homozygous Heterozygous
Family 2 III4 c.547G>A p.Gly183Ser Homozygous Heterozygous
Family 2 IV1 D c.547G>A p.Gly183Ser Homozygous Heterozygous
Family 2 IV1 R c.547G>A p.Gly183Ser Homozygous Heterozygous
Family 2 IV2 D c.547G>A p.Gly183Ser Homozygous Heterozygous
Family 2 IV2 R c.547G>A p.Gly183Ser Homozygous Heterozygous
Familiala c.239C>G (tumor shows 
dic(9;20)(p11;q11.1))
p.Pro80Arg Homozygous Wild type
Sporadic c.77T>G p.Val26Gly Heterozygous Wild type
Sporadic c.77T>G p.Val26Gly Heterozygous Wild type
Sporadic c.77T>G p.Val26Gly Heterozygous Wild type
Sporadic c.197G>A p.Ser66Asn Homozygous ND
Sporadic c.239C>G p.Pro80Arg Homozygous Wild type
Sporadic c.239C>G p.Pro80Arg Homozygous Wild type
Sporadic c.239C>G p.Pro80Arg Homozygous Wild type
Sporadic c.547G>A p.Gly183Ser Homozygous ND
Sporadic c.548G>T p.Gly183Val Heterozygous Wild type
Sporadic c.1012G>T p.Gly338Trp Heterozygous Wild type
Sporadic c.1049_1051delAGTinsGTCCG = p.Gln350fs Heterozygous Wild type
Sporadic c.1100_1100+15 del16 (IVS9 splice) Heterozygous ND
ND, not determinable; germline DNA either not tested or not available. PAX5 mRNA sequence is available under  
accession NM_016734.
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ALL cases (one-third of which harbor focal PAX5 deletions)1, PAX5-
regulated genes in Pax5−/− mice16–19 and genes regulated during 
mouse B-lymphoid development20. As a limited set of genes is known 
to be regulated in both mouse pro-B cells and mature B cells and 
as the overlap between mouse and human PAX5-regulated genes is 
unknown, we used all previously published PAX5-regulated genes and 
genes regulated during mouse B cell development16–20 in an unbiased 
approach to explore the effects of the PAX5 mutations affect-
ing Gly183 on direct and indirect transcriptional targets of PAX5. 
This analysis showed striking enrichment of genes deregulated in 
PAX5-mutated, ETV6-RUNX1–positive ALL, genes activated and 
repressed by PAX5 (including CD19, CD72 and CD79A), and genes 
regulated during mouse B-lymphoid development in the signature of 
familial B-ALL with the PAX5 mutation encoding p.Gly183Ser versus 
sporadic B-ALL (Fig. 3d and Supplementary Figs. 6 and 7). We also 
analyzed the overlap of previously published data and the expression 
differences between the familial ALL tumor samples and other B-ALL 
cases stratified by PAX5 mutation status (Supplementary Fig. 8 and 
Supplementary Table 16). Together, our results suggest that the PAX5 
mutation encoding p.Gly183Ser results in attenuation of PAX5 func-
tion and deregulation of PAX5 target genes that is less severe than for 
the previously reported p.Pro80Arg and ∆2–6 alterations that result 
in marked or complete loss of PAX5 activity.
The PAX5 deletions, translocations and sequence mutations identi-
fied as somatic events in B-ALL commonly affect the DNA-binding 
and transactivation domains and result in complete loss or marked 
attenuation of PAX5 transcriptional activity but are rarely homozygous 
































































































































































































































Figure 3 Attenuated transcriptional activity of p.Gly183Ser PAX5. (a) Transcriptional activity of PAX5 variants compared to wild-type protein determined 
using a PAX5-dependent reporter gene assay in 293T cells. Bars show mean (± s.e.m.) luciferase activity from six individual experiments with triplicate 
measurements (for PAX5 p.Gly183Val and PAX5 ∆2–6, four experiments with triplicate measurements). Asterisks indicate significant differences 
calculated by Dunnett’s test (P < 0.0001). MIR, MSCV-IRES-mRFP empty vector; WT, wild type. (b) Transcriptional activity of PAX5 variants determined 
using CD79A-dependent sIgM expression in the mouse J558LµM plasmacytoma cell line. Percentages indicate the proportion of mRFP-positive cells that 
show sIgM expression. Bars show mean (± s.e.m.) sIgM expression in two individual experiments with three replicates each. Asterisks indicate significant 
differences calculated by Dunnett’s test (P < 0.0001). (c) PAX5-dependent reporter gene assay of wild-type and p.Gly183Ser PAX5 run in triplicate with 
or without cotransfection with 0.05 µg of vector encoding GRG4 as indicated. A p.Tyr179Glu PAX5 mutant that is deficient in binding to GRG4 and 
empty vector were used as controls. Asterisks indicate significant differences as determined by two-tailed t test (P < 0.0001). NS, not significant.  
(d) GSEA examining enrichment of genes known to be activated or repressed by PAX5 in experimental systems in the transcriptional profile of familial ALL. 
A representative heatmap is presented of genes shown to be activated by PAX5 in mouse B cells17, which were negatively enriched in the transcriptional 
signature of familial ALL compared to B-ALL cases (excluding ETV6-RUNX1 ALL; P < 0.01, FDR = 0.09; see also supplementary tables 19–21). 
Leading-edge genes in this gene set responsible for enrichment are SCAND1 to NR4A1. Four samples from family 2 (diagnostic and relapse samples 
from individuals IV1 and IV2) show differential expression of PAX5-activated genes compared to a group of 139 sporadic B-ALL cases. This indicates an 
effect of the mutation encoding p.Gly183Ser on PAX5 function. Red indicates high expression, blue represents low expression. PAX5 mutational status is 
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promotes the development of B-ALL in experimental models 
that are commonly affected by the acquisition of accompanying sec-
ond hits in PAX5 (ref. 21), indicating that profound loss of PAX5 
activity is commonly a central event in leukemogenesis. In contrast, 
the inherited PAX5 mutation encoding p.Gly183Ser results in modest 
attenuation of PAX5 activity in transcriptional reporter assays and is 
accompanied by somatic loss of the wild-type PAX5 allele due to 9p 
alterations during leukemogenesis. This model is also consistent with 
the finding of a significant association of somatic PAX5 hypomorphic 
mutations coincident with complete loss of the normal PAX5 allele in 
leukemic cells with absent 9p. These observations suggest that a severe 
reduction in PAX5 activity is incompatible with normal B-lymphoid 
development and is deleterious in carriers; by contrast, the partial 
hypomorphic allele encoding p.Gly183Ser is tolerated as a germline 
allele, but additional genetic events further reducing PAX5 activity 
are required to establish the leukemic clone. The universal finding 
of deletion of wild-type PAX5 in all familial ALL cases, rather than 
the acquisition of additional hypomorphic PAX5 mutations, suggests 
that a complete loss of wild-type PAX5 activity is required for develop-
mental arrest and loss of maturation. This notion is supported by 
our transcriptional profiling of J558LµM cells expressing p.Gly183Ser 
PAX5 and by familial leukemias showing deregulation of PAX5 target 
gene expression that is significant but less marked than that observed 
with known loss-of-function mutations. The differences in the tran-
scriptional profiles of some target gene panels were not as robust as 
in mouse model systems, presumably owing to inherent germline and 
somatic genetic and epigenetic variability in human leukemias. In 
addition, ongoing studies will be of interest to fully characterize the 
functional consequences of PAX5 octapeptide-domain mutations.
Our findings have clinical implications with regard to options 
for pre-implantation genetic diagnosis and the possible relevance of 
somatic 9p alterations as a harbinger of a germline PAX5 mutation. The 
recent identification of germline TP53 mutations in familial ALL20,22 
and the data presented here strongly implicating PAX5 mutations in a 
new syndrome of inherited susceptibility to pre-B cell ALL indicate that 
further sequencing of affected kindreds is required to define the full 
spectrum of germline variations contributing to ALL pathogenesis.
URLs. dbSNP137, http://www.ncbi.nlm.nih.gov/projects/SNP/; 
National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing 
Project, http://evs.gs.washington.edu/EVS/; European Genome-phenome 
Archive (EGA), http://www.ebi.ac.uk/ega/; public data portal for 
results from the St. Jude–Washington University Pediatric Cancer 
Genome Project, http://explore.pediatriccancergenomeproject.org/.
MeTHodS
Methods and any associated references are available in the online 
version of the paper.
Accession codes. Transcriptome and whole-exome sequencing 
data and SNP microarray data have been deposited in the European 
Genome-phenome Archive (EGA), which is hosted by the European 
Bioinformatics Institute (EBI), under accession EGAS00001000447. 
Mouse Affymetrix gene expression data are deposited in the Gene 
Expression Omnibus (GEO) under accession GSE45260.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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Subjects and samples. Family 1 was ascertained from the Memorial Sloan-
Kettering Cancer Center Clinical Genetics Service. Study subjects provided 
written informed consent as part of a study to define genomic causes of 
lymphoid malignancies, and the study was approved by the local research 
ethics board. Family 2 from St. Jude Children’s Research Hospital was ascer-
tained in accord with local institutional review board approval. To protect 
subject identity, pedigrees were anonymized by alterations that do not affect 
genetic analysis.
Exome sequencing. Germline DNA (1 µg) from the peripheral leukocytes of 
affected individuals in remission and unaffected family members was used 
for whole-exome capture using an Agilent SureSelect 45Mb or 50Mb kit and 
paired-end sequencing with the Illumina HiSeq 2000 (ref. 23). Family 1 exome 
data were analyzed using Burrows-Wheeler Aligner (BWA)24 to align fastq 
files and generate BAM files, and the Genome Analysis Tool Kit (GATK)23,25 
was used for variant calling. SNP clustering and proximity to indels and the 
proportion of aligned reads at a site with mapping quality of zero were used 
for filtering variants. Variant quality score–recalibrated (VQSR) data were then 
processed using the SNPEff program for functional annotation. Samples from 
family 2 underwent variant analysis as previously described20. Downstream 
analysis consisted of filtering out low-quality variant calls and those already 
reported in public databases. The downstream processing of sequence data, 
variant annotation and the filtering strategy based on a presumed autosomal 
dominant mode of inheritance with incomplete penetrance are detailed in the 
Supplementary Note.
Principal-component analysis. From the exome-sequenced samples, single-
nucleotide variants seen at a frequency above 5% in the dbSNP database were 
selected for principal-component analysis. These data were then combined 
together with 1000 Genomes Project SNP data. SNPs were pruned on the 
basis of pairwise linkage disequilibrium within a 50-kb window. Data were 
transformed to calculate eigenvectors and eigenvalues for each sample, and 
the first two principal components were plotted.
SNP array genotyping. SNP array genotyping was performed using Affymetrix 
SNP 6.0 microarrays on the diagnostic leukemic sample from individual IV6 
from family 1 and on germline DNA from unaffected individuals III3, III4 and 
IV9 and analyzed using the Genotyping Console (Affymetrix). SNP 6.0 arrays 
were also performed for diagnostic leukemic and remission samples from 
individuals IV1, IV2 and III4 from family 2, as well as on relapse samples from 
IV1 and IV2, and data were analyzed by optimal reference normalization26 
and circular binary segmentation27,28 as previously described29 using R and 
dChip30. Haplotype analysis was conducted using germline samples from III3, 
III4 and IV9 and the diagnostic leukemic sample from IV6 from family 1 and 
the diagnostic and remission samples from IV1, IV2 and III4 from family 2.
In view of the cytogenetic abnormalities in each of the leukemic samples 
resulting in monosomy 9p, for which Sanger sequencing of the variant encod-
ing p.Gly183Ser demonstrated loss of heterozygosity with retention of the 
mutant allele, we were able to biologically phase the SNP risk haplotype con-
taining the mutant allele. Beagle phased haplotypes from the 1000 Genomes 
Project were analyzed for the five-SNP shared haplotype, and frequencies were 
estimated among the populations in HapMap.
PAX5 sequencing. Sanger sequencing (primer sequences available upon 
request) of the entire ORF of PAX5 was performed in 44 cases of sporadic ALL 
characterized by i(9) or dic(9;v) and 31 cases of familial cancer. We also reviewed 
the coding regions of PAX5 in an additional 8 families that had been exome 
sequenced or B-ALL cases that had been Sanger sequenced (n = 87 treatment-
resistant adult-onset ALLs) as part of other studies. Cases were acquired from St. 
Jude Children’s Research Hospital (Memphis, Tennessee; n = 34 i(9) or dic(9;v) 
and 28 familial cases), Memorial Sloan-Kettering Cancer Center/Columbia 
University (New York, New York; n = 2 i(9) or dic(9;v) and 87 treatment-resistant 
adult-onset ALLs), Radboud University Nijmegen Medical Centre (Nijmegen, 
The Netherlands; n = 6 i(9) or dic(9;v)), Texas Children’s Cancer Center 
and Human Genome Sequencing Center (Houston, Texas; 7 familial cases), 
Children’s Cancer Institute Australia for Medical Research (Sydney, Australia; 
n = 2 i(9) or dic(9;v) and 3 familial cases) and the Huntsman Cancer Institute/
Primary Children’s Medical Center (Salt Lake City, Utah; 1 familial case).
DNA constructs. The CD19 luciferase construct used for PAX5-dependent 
reporter gene assays contains copies of a high-affinity PAX5-binding site 
(derived from the CD19 promoter)14 and was a kind gift from M. Busslinger. 
The pFLAG-CMV2-Grg4 construct was a kind gift from G. Dressler31. The 
mutations encoding p.Gly183Ser and p.Gly183Val were introduced into 
the pSG5_PAX5-WT, MSCV-IRES-mRFP–PAX5-WT and pMSCV-Puro-
IRES-GFP–PAX5-WT vectors by site-directed mutagenesis (QuikChange, 
Agilent Technologies). For retroviral expression, wild-type PAX5 and other 
mutant cDNAs were subcloned as an XhoI-EcoRI fragment into MSCV-Puro- 
IRES-GFP (MSCV-PIG) or MSCV-IRES-RFP vector.
Cells and antibodies. HEK293 (ATCC CRL-1573) and HEK293T (ATCC 
CRL-11268) cells were maintained in Iscoves Modified Dulbecco’s medium 
supplemented with 10% FCS and streptomycin. Parental J558 cells (ATCC 
TIB-6) were grown in DMEM with 10% horse serum32. J558LµM cells have been 
generated from a subline (J558L) that had lost immunoglobulin heavy chain 
expression by infection with virus encoding a cDNA of the membrane-bound 
heavy-chain isoform33 and were grown in RPMI 1640 medium (Invitrogen) 
supplemented with 10% FBS (Hyclone), 2 mM L-glutamine (Invitrogen), 
50 mg/ml gentamicin (Invitrogen), 0.3 µg/ml xanthine (Sigma) and 1 µg/ml 
mycophenolic acid (Sigma) as previously described1,34. Both lines (parental 
J558 and J558LµM) do not normally express sIgM because they lack expres-
sion of CD79A35, but partial expression of CD79A can be induced by exo-
genous expression of PAX5, leading to the upregulation of sIgM13. Retroviral 
supernatants were produced by transient transfection of Phoenix Eco cells 
with MSCV-PIG-PAX5 constructs and were used to infect J558 cells by 
spinoculation in the presence of 4 µg/ml polybrene. Rabbit monoclonal anti-
body to PAX5 (ab109443) and mouse monoclonal antibody to Flag (ab18230) 
were purchased from Abcam and were used at a 1:250 and 1:500 dilution, 
respectively. Mouse monoclonal antibodies to β-actin (sc-1615) were pur-
chased from Santa Cruz Biotechnology and to SF2 were purchased from Zymed 
(32-4500) and were used at a 1:1,000 dilution. Antibodies to IgM conjugated 
to R-phycoerythrin (PE) (553409) or allophycocyanin (APC) (550676) were 
obtained from BD Pharmingen (BD Biosciences).
Subcellular fractionation. Protein expression and subcellular localization of 
the wild-type and p.Gly183Ser PAX5 proteins were examined using lysates 
from transiently transfected HEK293 cells separated by sucrose density gradi-
ent. The protocol for the separation of nuclei by sucrose gradient was adapted 
from the one for the Nuclei PurePrep Isolation kit (Sigma). CF buffer (10 mM 
Tris-HCl, 1 mM MgCl2, 1 mM DTT, 10 µM PMSF) and 1.8 M Sucrose Solution 
(Sigma) were used to create density layers for resolved separation by ultra-
centrifugation. Fractions were then subjected to SDS-PAGE and immunoblot-
ting with various antibodies to confirm adequate separation of nuclear and 
cytosolic fractions and to determine localization of recombinant PAX5.
Luciferase assays. We transfected 293T cells with MIR/MSCV-PIGWT or MIR/
MSCV-PIGmutant along with luc-CD19 and pRL-TK Renilla luciferase plasmid 
DNA (Promega) using FuGene 6 (Roche Diagnostics). For GRG4 repression 
assays, 500 ng of either the MSCV-PIG empty vector or of MSCV-PIG–PAX5-
WT, MSCV-PIG–PAX5-Gly183Ser or MSCV-PIG–PAX5-Tyr179Glu, 2 µg of 
luc-CD19 construct and 0.1 µg of pRL-TK Renilla luciferase plasmid were 
cotransfected with or without 50 ng of cDNA for GRG4 in pFLAG-CMV2 into 
HEK293T cells using X-tremeGENE HP DNA Transfection Reagent (Roche 
Diagnostics). Forty-eight hours after transfection, cell lysis and measure-
ment of firefly and Renilla luciferase activity was performed using the Dual-
Luciferase Reporter Assay System (Promega) according to the manufacturer’s 
instructions. All transfections were performed in triplicate in at least two 
independent experiments. Firefly luciferase activity was normalized accord-
ing to corresponding Renilla luciferase activity and reported as mean relative 
luciferase units (RLU) ± s.e.m.
Flow cytometry analysis. J558LµM cells transduced with MIR-PAX5 vectors 



























were analyzed for RFP (MIR) or GFP (pMSCV-PIG) and sIgM expression after 
staining with PE- or APC-conjugated antibodies to IgM (1:20, BD Pharmingen) 
using LSRII or Fortessa flow cytometers (Becton Dickinson).
Gene expression profiling. RFP-positive fractions of J558LµM cells transduced 
with empty MIR vector or vector expressing wild-type, ∆2–6, p.Pro80Arg, 
p.Gly183Ser or p.Gly183Val PAX5 (n ≥ 6 replicate transductions) were flow 
sorted, expanded and purity checked, and mRNA was extracted from 5–10 × 
106 cells using TRIzol (Invitrogen). mRNA was quantified by spectrophoto-
metry, and integrity was assessed using a 2200 Tapestation instrument 
(Agilent Technologies). Expression of wild-type and mutant PAX5 alleles was 
verified by RT-PCR and sequencing, and by immunoblotting. Gene expres-
sion profiling was performed using Mouse 430v2 PM arrays (Affymetrix) 
as previously described20. Statistical analyses, principal-component analysis 
and unsupervised hierarchical clustering were performed using R 2.15.2 
(ref. 36), Bioconductor 2.6 (ref. 37) and Spotfire Decision Site 9.1.1 (Tibco), 
and Partek Genomics Suite version 6.5 (6.11.0207). Data were normalized 
upon import using the Robust Multi-array Average algorithm38. To adjust for 
batch effects introduced by isolation and plate batches, we further corrected 
probe set signals with ComBat39, which applies an empirical Bayes framework 
for adjusting data for batch effects. Probe sets with signal not above the back-
ground level (twice the average signal for the control probes with different 
GC content) across all samples were excluded from differential expression 
analysis using limma40 with estimation of false discovery rate (FDR)41. For 
Gene Set Enrichment Analysis (GSEA)42, we used gene sets obtained from 
the Molecular Signatures Database v3.0, Hardy Fraction (GSE38463)20 and 
previous PAX5 studies16–19. Gene sets with less than 10 or more than 500 
genes were excluded, and significantly enriched gene sets after 1,000 per-
mutations at an FDR of <0.25 are reported. P values were calculated using 
ANOVA with Dunnett’s post hoc comparing each mutant allele to the wild-type 
allele. We also analyzed the overlap with the data from Revilla-i-Domingo 
et al.17 and the expression differences between wild-type PAX5, empty vector 
(MIR) and the PAX5 mutants p.Gly183Ser, p.Gly183Val, p.Pro80Arg and ∆2–6 
(Supplementary Tables 17 and 18). For the analysis of the sIgM-express-
ing subset, J558 cells infected with retroviruses expressing either wild-type 
PAX5 (n = 3), the p.Gly183Ser mutant (n = 4) or control MSCV-PIG empty 
vector (n = 3) were stained with PE-conjugated antibody to IgM and sorted 
for GFP and IgM (PE) double-positive cells (only single-positive GFP+ cells 
in the case of cells infected with the empty vector) on a FACSAria II cell 
sorter (BD Biosciences). Total mRNA was extracted using TRIzol accord-
ing to the manufacturer’s instruction, and gene expression profiling was 
performed using Affymetrix GeneCHIP Mouse Gene 1.0 ST arrays. All data 
analysis was performed using Partek Genomics Suite 6.5 (6.11.0207). Data 
were normalized upon import using RMA, and an ANOVA analysis was then 
performed to determine any differences between the conditions. One mutant 
sample was removed from the analysis because of its appearance as an outlier 
during principal-component analysis. The genes used for analysis were con-
strained to those genes previously identified as being PAX5 targets in mouse 
pro-B cells17. Genes were classified as being either activated or repressed by 
PAX5 (n = 122 and 237, respectively). Revilla-i-Domingo et al. also identified 
the most significant subsets of activated or repressed PAX5 targets (n = 20 
and 21, respectively)17. P values were calculated using the pbinom function 
in R 2.12.1.
Transcriptome sequencing. Transcriptome sequencing was performed on 
diagnostic and relapse samples obtained from 2 affected individuals in kin-
dred 2 and on 139 sporadic childhood B-ALL samples as described previ-
ously1,2,20. The 139 sporadic childhood B-ALL samples included ALLs with 
ETV6-RUNX1 fusion (n = 54), alteration of ERG (n = 22), hyperdiploidy with 
greater than 50 chromosomes (n = 1), hypodiploidy (n = 8), BCR-ABL1 fusion 
(n = 27) and BCR-ABL1–like characteristics (n = 27). PAX5 deletion and muta-
tion status was derived from whole-exome and/or whole-genome sequencing 
of all cases.
mRNA-seq library construction. Total RNA was extracted using TRIzol. Total 
RNA quality and quantity were assessed on Agilent RNA6000 Chips (Agilent 
Technologies) and Qubit (Invitrogen). A standard mRNA-seq library was 
prepared from 1 µg of total RNA following Illumina’s RNA-seq protocols, 
including DNase treatment and phenol purification, PolyA+ RNA selec-
tion using oligo(dT) beads, cDNA conversion, fragmentation by Covaris 
Ultrasonicator, end repair, deoxyadenosine tailing, adaptor ligation and PCR 
amplification (ten cycles). 10 pM of the library was clustered on an Illumina 
cBot and loaded into a flow cell on a HiSeq instrument for sequencing using 
the Illumina 2 × 100-bp sequencing kit.
Bioinformatic analysis. mRNA-seq paired-end reads were mapped to the 
human hg19 genome, RefSeq transcripts and known splice junctions using an 
in-house modified BWA mapping pipeline43. Transcript expression levels were 
estimated as fragments per kilobase of transcript per million mapped reads 
(FPKM), and gene FPKM values were computed by summing the transcript 
FPKM values for each gene using the Cuffdiff program available from the 
Cufflinks package44. We called a gene ‘expressed’ in a given sample if it had 
an FPKM value of ≥0.35 based on the distribution of FPKM gene expression 
levels and removed genes that were not expressed in any sample from the 
final gene expression data matrix for downstream analysis. We used FPKM44 
and limma40 to derive a gene expression profile for ALL with p.Gly183Ser-
mutated PAX5 compared to ETV6-RUNX1–negative B-ALL (Supplementary 
Table 19) and gene-set enrichment analysis to interrogate these expression 
profiles, including gene sets representing previously described genes acti-
vated and repressed by PAX5 (refs. 16–19) and genes regulated during mouse 
B-lymphoid development. As one-third of ETV6-RUNX1–positive ALL cases 
harbor focal PAX5 deletions (but not sequence mutations) that influence the 
expression of PAX5 target genes, we also incorporated gene sets of up- and 
downregulated genes in PAX5-mutated ETV6-RUNX1–positive ALL derived 
from the analysis of RNA-seq and whole-genome sequencing data for ETV6-
RUNX1–positive cases (Supplementary Tables 20 and 21). We also analyzed 
the overlap with the data from Revilla-i-Domingo et al.17 and the expression 
differences between the familial ALL tumor samples (FAMALL) and non-ETV 
B ALL wild type for PAX5 (nonETVBALL.PAX5WT), other B-ALLs wild type 
for PAX5 (OtherBALL.PAX5WT) and all B-ALL cases, including those with 
PAX5 mutations (OtherBALL) (Supplementary Table 16).
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